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Non-invasive delivery of therapeutic proteins and vaccines has proven an elusive goal for the researchers for the past few decades. These unique bio-pharmaceuticals are currently, mostly, administered by invasive mode that has fewer advantages in-terms of rapid onset of therapeutic action and no pre-systemic elimination but has numerous limitations. Apart from this, parenteral vaccines are of limited efficacy due to the need for repeated vaccination and they elicit only humoral immunity. To address these issues, a great deal of research is being carried out to develop painless and convenient methods for delivery of proteins and peptides. In the present work, it is aimed to design delivery systems, which can protect the proteins/peptides form degradation by enzymes and could deliver the protein within therapeutic concentration. We envisaged different strategies that include mucoadhesive colloidal carriers (liposomes, nano-particles) for trans-nasal and ocular routes and ligand coupled colloidal carriers for oral route as they will be taken up by Receptor Mediated Endocytosis (RME). The delivery systems were developed for various non-invasive routes such as nasal, ocular and oral and depending on results, the potential route would be explored thoroughly. To evaluate efficacy of these carriers, insulin and Hepatitis B surface antigen (HBsAg) were chosen as model drugs. In this regard present work encompasses to incorporate insulin/Hepatitis B surface antigen in colloidal carrier systems with and without mucoadhesive character and nano-constructs that would be coupled to targeting ligands/specific antigens. Thus present work utilizes two pronged strategies with a sole aim of developing an efficient transmucosal protein delivery carrier. Nevertheless, a successful carrier can have potential to develop as a platform delivery technology for protein bioactives. Insulin was chosen as a model drug it is most widely used drug of proteins category since diabetes mellitus is serious concern for millions of people all around the world and also because of its well defined properties and delivery requirements. The tests for identification showed that the insulin supplied by Serological Corporation, UK compiles with the USP standard of and was considered to be pure. The solubility studies of insulin showed amphiphilic nature and pH dependent solubility and was freely soluble in aqueous media of different pH. The linearly regressed standard curves of insulin were constructed by BCA Assay, HPLC and ELISA methods. BCA method is advantageous, as it doesn’t interact with many substances like the Folin-Ciocalteu reagent, especially detergents and buffers. A standard linear regression equation (Y = 0.0039x + 0.0307) in the concentration range of 5–400 g/ml was obtained with a good correlation (R2 = 0.99). The developed HPLC method in the present study is simple, sensitive and reproducible. The retention time of insulin was 6.29±0.25 minutes and the calibration graph was rectilinear in the concentration range of 1 g/ml to 40 g/ml (r2> 0.99). Enzyme immunoassay methods were used for quantitative and qualitative estimations of human insulin in rat serum. Insulin ELISA is a solid phase two site enzyme immunoassay based on the direct sandwich technique in which insulin reacts with peroxidase-conjugated anti-insulin antibodies followed by streptavidin HRP complex and anti-insulin antibodies. The calibration curve (y = 0.2482Ln(x) + 0.66) of insulin in PBS showed a linear response (r2 = 0.99) in the concentration range of 5 - 200 µIU/ml. The standard curve (Y = 0.3076 Ln(x)–0.0679) of human recombinant insulin in the plasma of STZ induced diabetic rats was also constructed and showed linear response (r2= 0.98) without any cross interference with rat insulin. 
HBsAg was chosen as model vaccine as this protein has great potential, especially an efficient carrier helps in mass vaccination programme in developing countries. The certificate of analysis supplied with HBsAg antigen complies with Pharmacopoeial, WHO and Standard products for potency, safety and stability. Further the antigenicity of the HBsAg was cross checked by ELISA method and complies with the manufacturer’s COA. A standard curve was constructed by BCA method (y = 0.0114x + 0.0203; R2>0.99) and was used for the drug content determination and release studies. The Calibration graph (y = 8E-05x + 0.0032; R2 = 0.99) of HBsAg was rectilinear in the concentration range of 100-2500 g/ml. The Calibration graph (y = 0.0027x + 0.1658, R2 = 0.97) for the estimation of anti-HBsAg antibodies was also plotted with a linear response in the concentration range of 100-2500 IU/ml.
Multivesicular liposomes despite being a versatile sustained release delivery vehicle (MVLs) were not tested for transmucosal delivery. This may be presumed to the fact that they themselves are negatively charged, and the possible transmucosal clearance of MVLs would drain the significant amount of encapsulated protein. It has been demonstrated that mucoadhesive carriers significantly enhances therapeutic efficacy and the overall bioavailability of insulin. Chitosan and carbopol were selected as coating materials so as to design carriers required for mucoadhesion. Thus, part of the present work endeavors to design an effective mucoadhesive carrier for transmucosal insulin delivery by combining advantages of MVLs and mucoadhesive polymers, and extending scope of the work to explore suitable route of administration.   
Multi vesicular liposomes were prepared using different lipid compositions by varying ampiphilic lipid such as DPPC and DSPC and neutral oils such as tricaprin or tributyrin along with cholesterol and DPPG (negatively charged lipid) as common components.  Protein loading is very high with MVL carriers (56-62%) compared to conventional liposomes (21.73%) and may be presumed to versatile feature of MVLs such as size and structure that has high aqueous volume. Encapsulation efficiency of insulin was 45.37% when DPPC is used whereas it was increased to 58.25% when DPPC is replaced by DSPC a long carbon chain lipid. The higher drug content of chitosan coated MVLs (56.25%) compared to carbopol coated MVLs may be presumed to be association of insulin with chitosan present on the surface. Further the coating process did not alter the integrity of entrapped protein significantly. 
The size of MVLs was found to be many fold higher compared to (26-34 m volume mean diameter) compared to conventional liposomes. A relatively higher polydispersity of MVLs (0.21-0.37) compared to conventional liposomes may be due to large size of MVLs. Size of MVLs increased after coating with mucoadhesive polymers, however the increase is insignificant considering the large size and polydispersity of MVLs which, suggest that no aggregation of liposomes during the polymer coating process. 
The MVLs made of tributyrin had a average Zeta Potential of –41.7, whereas replacement of tributyrin with tricaprin, a longer chain neutral lipid, further increase the zeta potential to –53.6. On the other hand conventional MVLs had very less negative zeta potential (–8.1). The average zeta potential of non-coated MVLs were changed from –41.7 (MVLs-TB) to +43 mv (CS-MVLs-TB) after coating with chitosan, whereas it has changed from –41.7 to –38.9 (CS-MVLs-TB) in case of carbopol coating. The positive zeta potential of chitosan coated MVLs mainly attributes to the electrical charge of the polymers fixed on the surface of the MVLs by an ion complex formation of chitosan with phosphatidyl glycerol present on the surface of the liposomes. The hydrogen bonding of hydroxyl group of carbopol and wander wall’s interaction might be responsible for the association of this negatively charged polymer on negatively charged MVLs. 
The mucoadhesive function provides long term contact of delivery system to the administration site and is offered by the polymer layer fixed on the surface of the MVLs because non-coated liposomes showed negligible adhesion compared to coated formulations. Interpenetration between the polymeric and the mucous network is considered to be responsible for the adhesion. In vitro study shows, percent Mucoadhesion increases with increase in polymer concentration up to 1% polymer concentration thereafter increase was insignificant. Carbopol formulation also showed significant adhesion, which may be presumed to viscosity related, and non specific interactions. The liposomal particles adhesion was in the order: CS–MVLs, CP–MVLs, negatively charged liposomes (Non Coated). 
MVLs carriers protect encapsulated insulin (85%) against proteolytic enzyme (aminopeptidase) in vitro whereas free insulin solution used as control was found to be completely degraded. The protection was comparatively higher with coated MVLs formulation, which is presumed to the presence of coating layer. HBsAg loaded in the carrier also showed the similar protection effect against aminopeptidase. 
The in vitro release data showed that there is no dumping or rapid initial release of insulin form MVLs as generally observed with sustained released drug delivery system as shown by the conventional MLVs (around 30% release in 1 hr). MVLs were coated at pH 7.4, at this pH insulin acts as a negatively charged protein, hence it interacts with the positive charge of chitosan. As a result of this electrostatic interaction insulin attachment on the surface of CS-MVLs is more compared to CP-MVLs.  Therefore higher release is observed in 1st hr in case of CS-MVLs compared to CP-MVLs and as well as non coated MVLs due to dissociation of surface insulin. In the case of conventional liposomes, almost 90% of drug has been released in 12hrs compared to 38% of CS-MVLs. Upon coating of MVLs release is further sustained and release was 53% even after 96 hrs from coated formulations. MVLs contain tricaprin showed more sustained release (9 day) compared to tributyrin (7 days). Release of HBsAg from MVLs has followed a near zero order release profile for prolong period of time. It was much slower compared to insulin and the release was only 90% form CS-MVLs after 9 days compared to 97% of insulin release under similar conditions.  
In STZ induced diabetic rats, MVLs have shown sustained hypoglycemic action after mucosal (nasal/ocular) administration. These carriers effectively reduced the blood glucose level up to 48 hrs after nasal administration (65% of initial blood glucose), although, a marginal reduction of 79% (of initial blood glucose) until 72 hrs compared to, 12 hrs of non-coated MVLs. The hypoglycemic action of conventional liposomes started receding from 8 hrs (66% of initial) and control (plain insulin) has shown slight hypoglycemic effect initially. A maximum reduction of 60% was found with chitosan formulation (CS-MVLs) at 8 hrs compared to 56% of carbopol (CP-MVLs). Control MVLs formulation with no mucoadhesiveness have shown 45% reduction while conventional MLVs has shown a maximum of 40% reduction at 2 hr. The hypoglycemic effect is significantly higher P<0.05 compared to control group in case of chitosan & carbopol coated MVLs. Significant quantity of insulin was detected from 8 hrs onwards with chitosan formulation (CS-MVLs) with a maximum of 334.4 IU/ml at 24 hrs and was detected till 48hrs (134.24 IU/ml) and start receding from 72 hrs (31.1 IU/ml) onwards. ELISA detectable insulin levels were found to be higher with CS formulation than CP formulation (334.4 Vs 251.41 IU/ml at 8hr) compared to control formulations where levels were significantly less. Upon ocular instillation to cul-de-sac of rat eyes, once again CS has shown a better result in terms of reduction of blood glucose level compared to CP formulation and controls such as non coated MVLs and conventional liposomes. CS-MVLs have shown a 40% reduction up to 24 hrs and a marginal effect up to 48 hrs. The CP-MVLs have shown comparatively less activity (24% at 24 hrs), whereas control formulations have shown considerably activity in the initial hrs. Pharmacokinetic determination of insulin mirrored the results of pharmacodynamic studies. A maximum of 186.3 μIU/ml insulin was found at 8 hrs with CS-MVLs and was significantly less at 48 hrs (37.56 μIU/ml). Carbopol coated MVLs have shown a maximum of 111.3 μIU/ml insulin at 8 hrs, which, receded to 65.2 μIU/ml at 24 hrs. CS-MVLs showed a better effect after nasal administration compared to ocular route although it was statistically insignificant.  Since chitosan has both mucoadhesive and permeation enhancer properties, chitosan coated MVLs able to reduce the blood glucose level for longer period of time and were more effective compared to carbopol coated MVLs.
Since mucosal immunization produces a disseminated mucosal immune response, it is feasible to consider that most vaccines, which are currently given by systemic route and those currently under development, could be considered for non-invasive administration. Therefore, an attempt was made for mucosal immunization (nasal and ocular) using mucoadhesive MVLs carriers as this system has shown exciting results with insulin and also due to fact that this carrier has significant amount of HBsAg loading. MVL carriers systems were evaluated for salivary and plasma anti-HBS responses by determining anti HBsAg antibodies in the biologic fluids by ELISA method. Chitosan (CS-MVLs) and carbopol (CP-MVLs) coated MVL carriers and non coated-MVLs which demonstrated effective  insulin delivery potential were chosen for nasal as well as ocular immunization studies with HBsAg to determine the viable route for such system. CS-MVLs (390±45) showed a higher antibody titer compared to CP-MVLs (222±45) whereas non coated MVLs (64±40) showed a slight antibody response. Salivary and plasma antibody titers of MVLs formulations are significantly higher (p<0.01) than the plain HBsAg solution. The superior effect of CS-MVLs was mirrored after ocular administration of MVLs formulations.  CS-MVLs showed a plasma antibody titer of 180±90 at 8th week compared to 114±65 of CP-MVLs and were significantly higher with plain HBsAg administration. As seen with nasal administration, the antibody titer was diminished at 16th week with both the MVLs formulation. In a nut-shell, CS-MVLs formulation administered by nasal route demonstrated better antibody response. 
Antibodies of saliva represent secretory IgA produced locally and disseminating to other mucosal surfaces, whereas plasma antibody titers represent circulatory IgG. The mean anti HBsAg titers of plasma is higher than saliva titers with all MVLs formulations. However, the effects are significantly less compared to positive control i.e. s.c. administration of HBsAg at a dose of 0.125g is higher than 20g of MVLs formulations given by non-invasive route. 
In present study we made an attempt to evaluate the usefulness of starch NPs for nasal insulin delivery based on successful delivery was found with microspheres.  The Starch nanoparticles form a gel-like layer which is cleared slowly from the nasal cavity, resulting in a prolonged residence time of the drug formulation. It was speculated that an increased contact time could possibly increase the absorption efficiency of the drug. 
Starch NPs prepared by various methodologies and with variable cross-linking were prepared and further, studied for in vivo performance. Insulin & HBsAg were entrapped in the preformed polysaccharides nanoparticles by a post loading method. Insulin was loaded at 3% w/w conc. of the NPs. This methodology has an advantage that fragile protein molecules are protected from harsh processing barriers. 
Emulsion cross-linked particles were more uniform in size distribution as evident from relatively narrow PDI as well as smaller in size compared to NPs obtained with gel method. Cross-linking with epichlorohydrin in place of POCl3 further reduced the average size. Hence NPs of epichlorohydrin emulsion were further optimized to evaluate the effect of degree of cross linking (EE-L1-NPs, EE-L2-NPs, and EE-L3-NPs) on in vivo performance. The size of NPs was (EE-L1-NPs, EE-L2-NPs, and EE-L3-NPs) less compared to gel cross linked NPs (194-229nm Vs 810nm) i.e. it is higher with least Cross-linking.  
Insulin release from starch NPs showed first order diffusion controlled profile with a burst effect. The NPs of gel method release 81% of insulin in 12hrs whereas emulsion crosslinked particles showed a faster release (85-90% in 12 hrs). Thus, Particles of higher size showed a slower release due to increased diffusional path length. Moreover burst release was higher with emulsion crosslinked particles irrespective of type of Cross-linking agent, which is presumed to decrease in size. The degree of cross linking has an effect on insulin release and it was higher with NPs of least cross linking (EE-L3-NPs; 90% compared to EE-L1-NPs; 95% in 12 hrs).
One of the main reasons for the low bioavailability of nasal proteins and peptides, apart from the restricted transport across the epithelial membrane, is the limited time available for absorption within the nasal cavity due to mucociliary clearance. The particulate carriers capable of absorbing moisture such as cross linked polysaccharide particles become a bioadhesive gelled system, which provides a high local drug concentration in close contact with the epithelial absorptive surface. Moreover, the absorption of water from the mucus layer by the particulate carrier dehydrates the mucosal surface, and affects the passage of the drug through the paracellular tight junctions. As an extension, the present study investigates usefulness of starch nanoparticles as they have shown size dependent in vitro insulin release. Also, nanoparticles are expected to cover a grater surface area of nasal mucosa. Further, the dosage loss associated to nasal mucosa due to mucocillary clearance is expected to be less with nanoparticles compared to microspheres. Very fast release in the case of nanoparticles provides a greater concentration gradient at the absorptive surface that might enhance permeability of drugs via Para-cellular pathway and nullifies effects of pre systemic clearance of protein drugs. The hypoglycemic action EE–NPs is superior and prolonged with a maximum reduction of 65% basal plasma glucose at 1 hrs compared to 50% reduction of POE-NPs formulation. With both the emulsion formulations, there is a rapid onset, followed by significant reductions for 6hrs and receding thereafter. In a nut shell, the NPs formulations made from emulsion method showed higher results compared to gel method NPs irrespective of cross linker. This is presumed to the small size of emulsion particles, which is in line with in vitro faster insulin release of the present study, and previous reports. Furthermore, NPs obtained from epichlorohydrin, as a result of smaller size, showed better result compared to NPs prepared POCl3 cross linking. The estimation of plasma insulin levels mirrored the pharmacodynamic effects and peak plasma level (Cmax) at 1 hr, was found to be higher in the order of EE-NPs (263 µIU/ml)>POE-NPs (136 µIU/ml)>EG-NPs (75 µIU/ml)>POE-NPs (71 µIU/ml). The effect was sustained up to 8 hrs with EE-NPs. 
A similar trend in nasal insulin delivery was found with lysophosphatiydylcholine as a permeation enhancer. The hypoglycemic action of EE–NPs is superior with a maximum reduction of 55% basal plasma glucose at 1 hrs compared to 61% reduction of POE-NPs formulation. Significant reduction in plasma glucose level was found until 6hrs with EE-NPs which was superior compared to all other formulations. Similar to Na glycocholate co-administration EE-NPs showed higher plasma insulin levels (208 µIU/ml) compared to all other formulations. The data indicate that the hypoglycemic action of EE-NPs is higher when Na glycocholate was co administered compared to lysophosphatiydylcholine as permeation enhancers. Both the permeation enhancer showed a higher efficacy compared to insulin NPs without these agents. In order to optimize EE-NPs formulation, particles with 3 different arbitrary concentrations of epichlorohydrin cross linking [EE-L1-NPs (0.1ml), EE-L2-NPs (0.2ml) and EE-L3-NPs (0.3ml)] were investigated by assessing trans-nasal insulin. The results show better hypoglycemic profile with medium crosslinked EE-L2-NPs as the maximum reduction was sustained till 2 hrs. As expected, least crosslinked EE-L1-NPs showed a rapid and short duration effect, compared to slightly less but sustained action of highly cross lined EE-L3-NPs. Overall EE-L2-NPs showed a better and prolonged hypoglycemic effect compared to EE-L1-NPs and EE-L3-NPs. The formulation shows a nadir of 70% reduction plasma glucose with significant effects till 8 hrs. Average plasma insulin levels (Cmax) at 1hrs of EE-L2-NPs (351 µIU/ml) are higher compared to other NPs, EE-L1-NPs (304 µIU/ml) and EE-L3-NPs (263 µIU/ml). It is worth to mention here that ELISA method estimates insulin in its active confirmation towards antibodies compared with RIA methods, which measures higher levels due to total radioactivity of fragments & metabolites. Starch NPs along with permeation enhancer showed a rapid and sustained hypoglycemic action for 6 hrs. The trend is consistent with a size dependent faster release of insulin in vitro. Hence provides therapeutic concentrations for long time, and results in a better therapeutic effect. The degree of cross linking was found to affect the release and has an effect on in vivo performance. NPs obtained with a particular cross-linking of epichlorohydrin demonstrated superior effects in the presence of Na glycocholate as permeation enhancer compared to lysophosphatiydylcholine.
The main aim of the present study targets to develop an efficient transmucosal protein delivery carrier via different routes. In this regard, present study makes an attempt to develop some ligand coupled nano-constructs for the per oral protein delivery which are not reported previously. Most of the particulate carrier have poor uptake across the gastric mucosa hence very low bioavailability could be achieved. As a result, ligand meditated transcytosis of particulate carriers is the interesting line for per oral protein delivery. Previous studies in our laboratory indicate successful insulin delivery with Vitamin B12 and transferrin coupled dextran NPs. The present study evaluates transferrin coupled chitosan and starch NPs for insulin delivery while lectins (UAE Iand WGA) coupled dextran NPs for HBsAg via oral route. Transferrin coupled NPs would be taken up by enterocytes though RME (receptor mediated endocytosis) at duodenum while lectin coupled carriers would be target to peyer’s patches of GIT associated lymphoid tissue (GALT). 
The starch/chitosan nanoparticles were coupled with Tf and dextran NPs with lectins (WGA and UAE I) by amide linkage at 4oC using EDAC. After coupling, 35-45% protein is retained in the particles. Lectin coupled carriers will be taken by M-epithelial cells present in the peyer’s patches of gut associated lymphoid tissue (GALT). Insulin was loaded in conjugated NPs at 2% and 3% w/w ratio. The encapsulation efficiency was 61% in St-Tf NPs at 3% loading compared to 50% at 2%. Moreover, results indicate higher entrapment at high drug weight ratio’s may be presumed by a higher surface area available via a vis a higher surface drug on the particles. HBsAg was loaded at a dose level of 1% and 2% w/w of particles. The entrapment of HBsAg was low (30-38 %) compared to insulin (42-64%) i.e. much of the HBsAg was surface associated due to its large size, unable to permeate into the pores of nano-matrix.
Starch NPs used for coupling with ligands have shown small size (264nm) which is increased after coupling with transferrin (295 nm). Size of chitosan NPs was fond to be 279nm and was increased to 310 nm after coupling with transferrin. Particle size of Dextran system was changed from 191 nm to 291nm and 268 nm after coupling with WGA and UAE I respectively.
IR analysis reveals the probability of binding and was confirmed by X- ray photon correlation (XPS) spectroscopy. The survey XPS scans exhibited the summary of the chemical compositions of the nano-particles surface up to 5nm depth. The relative intensity of the signals detected reflects the relative concentration of the elements present on the surface. Tf and WGA lectin binding to the particles was confirmed by the presence of nitrogen atom on the surface of the NPs. XPS analysis of Starch NPs shows increase in oxygen content after carboxylation and change in the ratio of nitrogen (N), and sulphur (S) in the conjugates. The surface analysis of uncoupled chitosan NPs particles showed mass concentrations of carbon (73.1%), oxygen (24.2%) and nitrogen (2.6%).  Whereas after coupling, nitrogen was increased to a level of 4.73% along with sulphur (3.1%) and a corresponding relative decrease of carbon (64.1%) indicating Tf attachment. Transferrin was coupled at 2-2.5 % w/w of NPs whereas UAE I and WGA derivatives were bound in the range of 1.6–1.8 % w/w of the particles. 
The effect of gastric proteolytic enzymes (pepsin, trypsin and chymotrypsin) was studied in vitro on the ligand coupled NPs to investigate the protective action of carrier system. Degradation was significantly less in the case of pepsin incubation.  This is due to strong association of positively charged insulin (at acidic pH) with the carrier systems. St-Tf NPs and Ch-Tf protected 65-85 % of the entrapped protein. The degradation effect was more in the order of chymotrypsin >trypsin >pepsin. Plain insulin solutions were completely degraded under these conditions. HBsAg loaded NPs conjugates shown a similar protective profile against proteolytic enzymes.
In vitro release study shows a burst release of insulin from Ch-Tf conjugates and it was higher with 2% loading compared to 3%. A first order release profile with a burst effect for 24 hrs was observed for HBsAg from ligand coupled NPs conjugates. The release was faster in case of HBsAg compared to insulin and moreover the burst effect (30-35 % burst release) was also higher but incomplete. The presence of targeting ligands lowered the burst effect and release rate. 
Insulin loaded NPs conjugates (CS-Tf & St-Tf) were assessed for In vivo performance after oral administration to STZ rats and measuring blood glucose levels. A rapid and extensively prolonged effect was observed with both the NPs conjugates at investigated 2% & 3% w/w ratio. After oral administration, at a total dose of 20 IU/Kg ( 8-12 IU of entrapped) insulin, a nadir of 50–55% reductions was achieved in 6-8 hrs with both CS-Tf and St-Tf formulations. With both these formulations hypoglycemic effect was observed with a nadir of 60% reduction at 4 hrs and was declined faster after 8 hrs. The hypoglycemic effect was prolonged until 18 hours, with a 36% reduction of St-Tf compared to 30% of CS-Tf at 3% loading which is more prolonged upto 24hrs with St-Tf.  The overall activity of 2% and 3% loading is significantly higher (p < 0.01) than control group and also the hypoglycemic effect of 3% loading is significantly higher (p < 0.05) than 2% loading with both the formulations. Results demonstrate a strikingly higher effectiveness of 3% w/w insulin loading where; it has shown a slightly less activity with 2% loading. The results indicates St-Tf conjugates is more effective insulin carrier compared to chitosan conjugate although the difference was insignificant (P>0.05). Moreover, the study was conducted in fed diabetic animals, which showed significant reductions in glucose levels. Where as most of the previous studies were carried out in fasted animals. Therefore, we speculate a greater efficacy of this carrier system for treating diabetic compared to studies conducted in fasted models.
On the other hand, among the transferrin coupled NPs, CS-Tf (297±132) shown better immunization potential compared to St-Tf NPs (192±45) conjugates. An extension of this study evaluates dextran NPs Conjugates with lectins i.e. WGA & UAE I for oral immunization potential with HBsAg. Dex-UAE I NPs conjugates demonstrated superior immunization potential over Dex-WGA NPs. Moreover dextran-lectins system showed significantly higher response compared to both transferrin coupled starch and chitosan NPs. Overall, Dex-UAE I NPS conjugates were found to be superior to all other ligand NPs conjugates tested for oral HBsAg immunization potential with considerable antibody titer at 16th week. 
	
Finally, it can be concluded that, for insulin, the nasal delivery of mucoadhesive MVLs formulations was found to be superior compared to all other formulations tried via different routes. In this regard, chitosan coated MVLs showed a better effect after nasal administration compared to ocular route although it was statistically insignificant. These findings are very exciting as is insulin is delivered effectively to the systemic circulation via non-invasive route (i.e. nasal as well as ocular) in therapeutically effective level and would be useful in the complimenting the therapy of diabetic patients. Nevertheless, starch NPs along with permeation enhancer also demonstrated a sustained hypoglycemic action which is presumed to be rapid release of insulin form the NPs which are associated to a higher mucosal surface leading to greater concentration gradient at the absorptive area. The release rate and higher associated surface area might work in tandem, and might be greatly amplified when combined with permeation enhancers. In the case of HBsAg delivery, MVLs formulations (CS-MVLs & CP-MVLs) and some of the ligand-coupled nanoparticles (Dex-UAE I & Dex-WGA) have demonstrated moderate oral delivery potential with higher salivary and plasma responses.  The plasma antibody titers were higher than salivary antibody with all the tested formulations.  Sustained antibody titers were found with Dex-UAE I conjugates even after 16th week. These results imply that Cs-MVLs and Dex-UAE I NPs conjugates have shown a non invasive delivery potential i.e. close to the lower parenteral dose of the soluble antigen (0.125g S.C).  However, the antibody titers are not sufficient for a protective response. Hence, improvements have to be made by optimization of the delivery system for better entrapment of the antigen and administering smaller doses with many boosters. The delivery can be enhanced by multiple smaller doses and improving antigen entrapment in the carrier systems. Transferrin coupled Starch and chitosan NPs showed lesser responses compared to dextran-lectins conjugates, which needs further investigation. In a nut-shell, the outcome of present study is the exciting prospect of polymer coated MVLs for trans-nasal insulin delivery. Also this is the first successful report of MVLs as non-invasive delivery carriers. It must be emphasized here that the protein delivery via trans-nasal mode is less complicated compared to all other non-invasive modes of administration and there is a grater scope for reliable and reproducible results. On a different note, starch NPS for nasal insulin delivery and dextran lectin conjugates for HBsAg vaccine have shown moderate results, which is worth of further optimization. However these studies need further optimization and scale-up considerations to develop efficient trans-mucosal drug delivery carriers that lead to elaborated animal trials. 




